News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
613,701 Results
Type
Article (37186)
Company Profile (125)
Press Release (576390)
Section
Business (172706)
Career Advice (2749)
Deals (32405)
Drug Delivery (85)
Drug Development (72731)
Employer Resources (156)
FDA (15602)
Job Trends (14576)
News (300404)
Policy (29077)
Tag
Academia (2651)
Alliances (43275)
Alzheimer's disease (1329)
Approvals (15570)
Artificial intelligence (174)
Bankruptcy (282)
Best Places to Work (12102)
Breast cancer (215)
Cancer (1567)
Cardiovascular disease (120)
Career advice (2277)
CAR-T (113)
Cell therapy (330)
Clinical research (58539)
Collaboration (606)
Compensation (313)
COVID-19 (2504)
C-suite (147)
Data (1526)
Diabetes (190)
Diagnostics (6468)
Earnings (66745)
Employer resources (137)
Events (100384)
Executive appointments (532)
FDA (16411)
Funding (530)
Gene therapy (225)
GLP-1 (556)
Government (4035)
Healthcare (19783)
Infectious disease (2599)
Inflammatory bowel disease (118)
Interviews (538)
IPO (16078)
Job creations (2925)
Job search strategy (1895)
Layoffs (397)
Legal (6433)
Lung cancer (229)
Manufacturing (210)
Medical device (13868)
Medtech (13873)
Mergers & acquisitions (16714)
Metabolic disorders (449)
Neuroscience (1701)
NextGen: Class of 2025 (6715)
Non-profit (4821)
Northern California (1939)
Obesity (233)
Opinion (216)
Parkinson's disease (111)
Patents (139)
People (51173)
Phase I (18198)
Phase II (25951)
Phase III (19464)
Pipeline (616)
Postmarket research (2057)
Preclinical (7401)
Radiopharmaceuticals (251)
Rare diseases (304)
Real estate (4912)
Regulatory (20160)
Research institute (2439)
Resumes & cover letters (449)
Southern California (1690)
Startups (3043)
United States (17355)
Vaccines (546)
Weight loss (147)
Date
Today (113)
Last 7 days (609)
Last 30 days (2518)
Last 365 days (35615)
2025 (2501)
2024 (36064)
2023 (41365)
2022 (52232)
2021 (57141)
2020 (55647)
2019 (48778)
2018 (36683)
2017 (32197)
2016 (30464)
2015 (35549)
2014 (24805)
2013 (19331)
2012 (20850)
2011 (21634)
2010 (18715)
Location
Africa (762)
Arizona (131)
Asia (35915)
Australia (6398)
California (4400)
Canada (1594)
China (363)
Colorado (199)
Connecticut (221)
Europe (83245)
Florida (636)
Georgia (162)
Illinois (433)
Indiana (252)
Maryland (691)
Massachusetts (3465)
Michigan (207)
Minnesota (323)
New Jersey (1244)
New York (1256)
North Carolina (851)
Northern California (1939)
Ohio (163)
Pennsylvania (1023)
South America (1089)
Southern California (1690)
Texas (644)
Utah (133)
Washington State (442)
613,701 Results for "astrazeneca ab".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcast
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.
November 13, 2024
·
1 min read
·
Heather McKenzie
Prostate cancer
AstraZeneca’s Truqap Redeems Itself with Phase III Prostate Cancer Win
Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It helps AstraZeneca position itself as a top player in the prostate cancer space, alongside its Big Pharma colleagues.
November 26, 2024
·
2 min read
·
Tristan Manalac
China
AstraZeneca’s Stock Price Takes a Hit as China Chief Investigated for Insurance Fraud
BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” to AstraZeneca, but contends that the share selloff is “overdone” and likely a knee-jerk reaction by investors.
November 6, 2024
·
2 min read
·
Tristan Manalac
Cancer
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus will reveal promising mid-stage data for their respective cancer candidates.
December 2, 2024
·
4 min read
·
Tristan Manalac
Obesity
AstraZeneca Bolsters Obesity Pipeline With Promising Early Data for Candidates
While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb studies and creates a “foothold” for AstraZeneca in the weight loss space.
November 5, 2024
·
3 min read
·
Tristan Manalac
People
From Argentina to America: A Physician’s Journey to Pharma and AstraZeneca
Carlos Doti has moved countries and changed jobs, but one thing hasn’t changed. Making an impact on patient care has always been a priority for the AstraZeneca executive.
October 10, 2024
·
6 min read
·
Angela Gabriel
Approvals
AstraZeneca’s Imfinzi-Lynparza Combo Wins Landmark EU Nod for Endometrial Cancer
The European Union has approved the first-ever combination therapy consisting of an immunotherapy and a PARP inhibitor for the treatment of endometrial cancer, AstraZeneca announced Wednesday.
August 14, 2024
·
2 min read
·
Tristan Manalac
Cardiovascular disease
AstraZeneca Puts $2B On The Line for Preclinical Heart Disease Drug
For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million upfront and offering up to $1.92 billion in regulatory and commercial milestones.
October 7, 2024
·
2 min read
·
Tristan Manalac
Cancer
AstraZeneca’s Calquence Aces Phase III CLL Trial, Eyes Fixed-Duration Approval
AstraZeneca is seeking a fixed-duration approval for Calquence, which will allow patients with chronic lymphocytic leukemia to take breaks from the therapy and prevent excessive toxicities and drug resistance.
July 30, 2024
·
2 min read
·
Tristan Manalac
Adcomms
FDA Flags Potential ‘Overtreatment’ for NSCLC With AstraZeneca’s Imfinzi Ahead of Adcomm
AstraZeneca is proposing to use Imfinzi for resectable non-small cell lung cancer in the perioperative setting—both before and after surgical resection of the tumor. However, ahead of Thursday’s advisory committee meeting, FDA staffers have expressed concerns.
July 24, 2024
·
2 min read
·
Tristan Manalac
1 of 61,371
Next
